Perrigo Co. PLC (PRGO): Price and Financial Metrics
PRGO Price/Volume Stats
Current price | $32.19 | 52-week high | $40.28 |
Prev. close | $31.46 | 52-week low | $25.77 |
Day low | $31.48 | Volume | 1,583,458 |
Day high | $32.35 | Avg. volume | 2,021,813 |
50-day MA | $31.13 | Dividend yield | 3.56% |
200-day MA | $32.32 | Market Cap | 4.36B |
PRGO Stock Price Chart Interactive Chart >
PRGO POWR Grades
- PRGO scores best on the Growth dimension, with a Growth rank ahead of 96.57% of US stocks.
- The strongest trend for PRGO is in Growth, which has been heading down over the past 26 weeks.
- PRGO ranks lowest in Momentum; there it ranks in the 6th percentile.
PRGO Stock Summary
- PERRIGO CO PLC's market capitalization of $4,516,431,278 is ahead of 72.72% of US-listed equities.
- PRGO's went public 32.07 years ago, making it older than 83.07% of listed US stocks we're tracking.
- Over the past twelve months, PRGO has reported earnings growth of 1,870.83%, putting it ahead of 99.55% of US stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to PERRIGO CO PLC are SJM, JCTCF, NARI, LIVE, and IIIV.
- PRGO's SEC filings can be seen here. And to visit PERRIGO CO PLC's official web site, go to www.perrigo.com.
PRGO Valuation Summary
- PRGO's price/sales ratio is 0.9; this is 59.09% lower than that of the median Healthcare stock.
- Over the past 243 months, PRGO's price/earnings ratio has gone down 1085.4.
Below are key valuation metrics over time for PRGO.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
PRGO | 2023-12-29 | 0.9 | 0.9 | -1063.6 | 41.5 |
PRGO | 2023-12-28 | 0.9 | 0.9 | -1060.9 | 41.4 |
PRGO | 2023-12-27 | 0.9 | 0.9 | -1059.3 | 41.4 |
PRGO | 2023-12-26 | 0.9 | 0.9 | -1049.3 | 41.2 |
PRGO | 2023-12-22 | 0.9 | 0.9 | -1047.7 | 41.1 |
PRGO | 2023-12-21 | 0.9 | 0.9 | -1038.1 | 40.9 |
PRGO Growth Metrics
- Its 4 year net cashflow from operations growth rate is now at -6.25%.
- The 5 year price growth rate now stands at -23.53%.
- Its 2 year cash and equivalents growth rate is now at 285.09%.
The table below shows PRGO's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 4,451.6 | 307.3 | -140.6 |
2022-09-30 | 4,401.3 | 16 | -107.3 |
2022-06-30 | 4,343.8 | 300.6 | -116.8 |
2022-03-31 | 4,203.2 | 235.2 | -109.4 |
2021-12-31 | 4,138.7 | 156.3 | -68.9 |
2021-09-30 | 4,323.3 | 372.1 | -253.5 |
PRGO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PRGO has a Quality Grade of D, ranking ahead of 9.21% of graded US stocks.
- PRGO's asset turnover comes in at 0.394 -- ranking 119th of 682 Pharmaceutical Products stocks.
- TMBR, OCUP, and ORMP are the stocks whose asset turnover ratios are most correlated with PRGO.
The table below shows PRGO's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-07-03 | 0.394 | 0.359 | -0.038 |
2021-04-03 | 0.407 | 0.359 | -0.012 |
2020-12-31 | 0.435 | 0.359 | -0.003 |
2020-09-26 | 0.439 | 0.358 | 0.026 |
2020-06-27 | 0.440 | 0.357 | 0.064 |
2020-03-28 | 0.440 | 0.361 | 0.058 |
Perrigo Co. PLC (PRGO) Company Bio
Perrigo Company plc is an American Irish–registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. (Source:Wikipedia)
Latest PRGO News From Around the Web
Below are the latest news stories about PERRIGO CO PLC that investors may wish to consider to help them evaluate PRGO as an investment opportunity.
Medtronic (MDT) Up 2.9% Since Last Earnings Report: Can It Continue?Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Perrigo (PRGO) Up 2% Since Last Earnings Report: Can It Continue?Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Perrigo Announces Early Results of Cash Tender Offer for NotesPerrigo Company plc (NYSE: PRGO) (the "Company"), a leading provider of Consumer Self-Care Products, today announced the early tender results of the previously announced cash tender offer (the "Tender Offer") by Perrigo Finance Unlimited Company, its wholly-owned finance subsidiary (the "Issuer"), to purchase its 3.900% Senior Notes due 2024 (CUSIP / ISIN Nos. 714295 AC6 / US714295AC63) (the "Notes") in a principal amount of up to $300,000,000. The terms and conditions of the Tender Offer are se |
Insider Buying Alert: EVP & CHRO Robert Willis Acquires Shares of Perrigo Co PLCIn the realm of stock market movements, insider trading activity is often a significant indicator that garners the attention of investors. |
Perrigo's (NYSE:PRGO) earnings trajectory could turn positive as the stock rallies 4.2% this past weekThe main aim of stock picking is to find the market-beating stocks. But in any portfolio, there will be mixed results... |
PRGO Price Returns
1-mo | 19.08% |
3-mo | 1.02% |
6-mo | 2.67% |
1-year | -5.01% |
3-year | -16.18% |
5-year | -24.25% |
YTD | 1.02% |
2023 | -2.47% |
2022 | -9.78% |
2021 | -10.95% |
2020 | -11.97% |
2019 | 35.65% |
PRGO Dividends
Ex-Dividend Date | Type | Payout Amount | Change | ||||||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Continue Researching PRGO
Here are a few links from around the web to help you further your research on PERRIGO Co plc's stock as an investment opportunity:PERRIGO Co plc (PRGO) Stock Price | Nasdaq
PERRIGO Co plc (PRGO) Stock Quote, History and News - Yahoo Finance
PERRIGO Co plc (PRGO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...